Orzeyful Approved for Narcolepsy
On Aug. 5, 2026, the US Food and Drug Administration (FDA) approved Takeda Pharmaceuticals’ Orzeyful™ (oveporexton) for the treatment of narcolepsy type 1 (NT1) in adults. Orzeyful is an oral orexin receptor 2 (OX2R)-selective agonist and the first approved therapy designed to restore orexin signaling by targeting the underlying orexin deficiency associated with NT1. It is intended to address the full range of NT1 symptoms, including excessive daytime sleepiness, cataplexy (sudden episodes of muscle weakness triggered by strong emotions), sleep paralysis, hallucinations, and disrupted nighttime sleep. The recommended dose is 1mg or 2mg taken orally upon awakening, followed by the same dose three to five hours later, with a maximum daily dose of 4mg. Following FDA approval, Orzeyful is awaiting scheduling by the US Drug Enforcement Administration (DEA), which is expected between October and mid-November 2026, with product launch anticipated shortly thereafter. Cost information is not yet available. Full prescribing information may be found here.
At a Glance
- Brand Drug: Orzeyful™ (oveporexton)
- Manufacturer: Takeda
- Date Approved: Aug. 5, 2026
- Indication: For the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adults
- Dosage Forms Available: 0.5mg, 1mg, and 2mg tablets
- Launch Date: Anticipated in late 2026, pending DEA scheduling
- Estimated Annual Cost: Not yet known.
- FDA Designation: Breakthrough Therapy. Priority Review.
- Narcolepsy is classified into type 1, which is associated with orexin deficiency and cataplexy, and type 2, which is characterized by excessive daytime sleepiness without cataplexy.
- NT1 is a chronic neurologic sleep disorder caused by the loss of orexin-producing neurons, resulting in excessive daytime sleepiness, cataplexy, disrupted nighttime sleep, sleep paralysis, and hallucinations.
- It is a rare disorder estimated to affect approximately 120,000 individuals in the United States.
- Approval was supported by the phase III FirstLight and RadiantLight studies in 273 adults with NT1, in which Orzeyful significantly improved daytime wakefulness and reduced cataplexy episodes compared with placebo.
- The most commonly reported adverse effects included insomnia, urinary frequency/urgency, and hypersalivation.
- This approval represents a potentially paradigm-shifting approach in narcolepsy treatment by addressing the underlying orexin deficiency that causes NT1, rather than symptom management alone.
- Symptom management includes wake-promoting therapies such as modafinil, armodafinil, and Sunosi® (solriamfetol – Axsome Therapeutics), while cataplexy is commonly treated with oxybate formulations such as Xyrem® (sodium oxybate – Jazz Pharmaceuticals, generics), Xywav® (calcium, magnesium, potassium, and sodium oxybates – Jazz Pharmaceuticals), and Lumryz™ (extended-release sodium oxybate – Avadel Pharmaceuticals). Wakix® (pitolisant – Harmony Biosciences), a histamine-3 receptor antagonist/inverse agonist, is approved for the treatment of excessive daytime sleepiness and cataplexy, and traditional stimulants such as amphetamines and methylphenidate are also used in clinical practice.
- Axsome’s reboxetine is a highly selective norepinephrine reuptake inhibitor in development for excessive daytime sleepiness and cataplexy due to narcolepsy, with approval possible in the first half of 2027.